Literature DB >> 7091938

Diffuse malignant mesothelioma. Prospective evaluation of 69 patients.

A P Chahinian, T F Pajak, J F Holland, L Norton, R M Ambinder, E M Mandel.   

Abstract

From 1974 to 1980, 69 patients with ith diffuse malignant mesothelioma were prospectively evaluated. The initial site of involvement was the pleura in 57 patients and the peritoneum in 12. Previous asbestos exposure was found in 53 patients (77%), with a shorter period of latency for peritoneal (mean, 28 years) than for ith pleural mesothelioma (mean, 35 years) than for pleural mesothelioma (mean, 35 years). Other associated exposure or diseases included talc, mica, familial Mediterranean fever, and diffuse lymphocytic lymphoma (one patient each). Thrombocytosis was common, as were thromboembolic episodes. Survival was significantly better for patients with an epithelial subtype, with pleural versus peritoneal mesothelioma, and for those under 65 years of age. Surgery was never curative, but its extent was correlated with survival and earlier diagnosis. Results of chemotherapy with doxorubicin and 5-azacytidine yielded a somewhat better survival rate than a combined program with doxorubicin and radiotherapy. Survival after chemotherapy was correlated with performance status, response to chemotherapy, and extent of previous surgery.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7091938     DOI: 10.7326/0003-4819-96-6-746

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  45 in total

1.  Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems.

Authors:  J G Edwards; K R Abrams; J N Leverment; T J Spyt; D A Waller; K J O'Byrne
Journal:  Thorax       Date:  2000-09       Impact factor: 9.139

2.  Mesothelioma and venous thrombosis.

Authors:  Mehlika Isildak; Gulay Sain Guven; Salih Emri
Journal:  CMAJ       Date:  2004-07-06       Impact factor: 8.262

3.  Phase II trial of 5,6-dihydro-5-azacytidine in pleural malignant mesothelioma.

Authors:  H M Dhingra; W K Murphy; R J Winn; M N Raber; W K Hong
Journal:  Invest New Drugs       Date:  1991-02       Impact factor: 3.850

Review 4.  Chemotherapy in malignant mesothelioma: a review.

Authors:  A Krarup-Hansen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

5.  Peritoneal mesothelioma: an unusual cause of an acute phase response presenting to the rheumatologist.

Authors:  S S Hamdulay; H T Cook; N Strickland; K A Davies; J C Mason
Journal:  Clin Rheumatol       Date:  2006-01-14       Impact factor: 2.980

Review 6.  Diagnosis, staging, and surgical treatment of malignant pleural mesothelioma.

Authors:  Michael Kent; David Rice; Raja Flores
Journal:  Curr Treat Options Oncol       Date:  2008-08-29

Review 7.  Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management.

Authors:  Terence C Chua; Tristan D Yan; David L Morris
Journal:  Can J Surg       Date:  2009-02       Impact factor: 2.089

8.  Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients.

Authors:  M R Law; A Gregor; M E Hodson; H J Bloom; M Turner-Warwick
Journal:  Thorax       Date:  1984-04       Impact factor: 9.139

9.  Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy.

Authors:  H Bielefeldt-Ohmann; A L Marzo; R P Himbeck; A G Jarnicki; B W Robinson; D R Fitzpatrick
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

Review 10.  Peritoneal mesothelioma: a review.

Authors:  Alessio Bridda; Ilaria Padoan; Roberto Mencarelli; Mauro Frego
Journal:  MedGenMed       Date:  2007-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.